Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension

[1]  J. Braszko,et al.  Effect of angiotensin II and vasopressin on acquisition and extinction of conditioned avoidance in rats , 2004, Psychopharmacology.

[2]  Hermine Lenoir,et al.  Hypertension and dementia , 2003, Current cardiology reports.

[3]  R. Fogari,et al.  Influence of losartan and atenolol on memory function in very elderly hypertensive patients , 2003, Journal of Human Hypertension.

[4]  H. Siragy.  Angiotensin receptor blockers: how important is selectivity? , 2002, American journal of hypertension.

[5]  M. Szklo,et al.  The relationship between temporal changes in blood pressure and changes in cognitive function: atherosclerosis risk in communities (ARIC) study. , 2002, Preventive medicine.

[6]  T. Unger,et al.  The renin-angiotensin system in the brain: possible therapeutic implications for AT1-receptor blockers , 2002, Journal of Human Hypertension.

[7]  R. Fogari,et al.  P-9: Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients , 2002 .

[8]  P. Gard.  The role of angiotensin II in cognition and behaviour. , 2002, European journal of pharmacology.

[9]  R. McKelvie,et al.  Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. , 2002, Journal of the American College of Cardiology.

[10]  S. Yusuf.  From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. , 2002, The American journal of cardiology.

[11]  P. Sleight.  Angiotensin II and trials of cardiovascular outcomes. , 2002, The American journal of cardiology.

[12]  L. T. Robertson.  Memory and the brain. , 2002, Journal of dental education.

[13]  J. Harding,et al.  A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits , 2001, Regulatory Peptides.

[14]  J. Connell,et al.  Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. , 2001, Journal of the American College of Cardiology.

[15]  K. Chopra,et al.  Comparative studies on the memory- enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm , 2001, Neuropeptides.

[16]  T. Inagami,et al.  The Renin-Angiotensin System in the Twenty-first Century , 2001, Blood pressure.

[17]  G. Paxinos,et al.  Distribution of angiotensin IV binding sites (AT4 receptor) in the human forebrain, midbrain and pons as visualised by in vitro receptor autoradiography , 2000, Journal of Chemical Neuroanatomy.

[18]  B. Winblad,et al.  The relationship between signs of cardiovascular deficiency and cognitive performance in old age: a population-based study. , 2000, The journals of gerontology. Series B, Psychological sciences and social sciences.

[19]  W. Elliott.  Therapeutic trials comparing angiotensin converting enzyme inhibitors and Angiotensin II receptor blockers , 2000, Current hypertension reports.

[20]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[21]  Shokei Kim,et al.  Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. , 2000, Pharmacological reviews.

[22]  M. Volpe,et al.  Angiotensin II AT2 subtype receptors: an emerging target for cardiovascular therapy. , 2000, Italian heart journal : official journal of the Italian Federation of Cardiology.

[23]  Michael A. Weber,et al.  Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin ii receptor antagonists in the treatment of hypertension , 1999 .

[24]  V. Dzau,et al.  The renin-angiotensin-aldosterone system: a specific target for hypertension management. , 1999, American journal of hypertension.

[25]  B. Trimarco,et al.  Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril. , 1999, Journal of hypertension.

[26]  D. Iarussi,et al.  Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. , 1999, American journal of hypertension.

[27]  P. Vanhoutte.  How to assess endothelial function in human blood vessels. , 1999, Journal of hypertension.

[28]  L. Stubley,et al.  Contributions of the Brain Angiotensin IV–AT4 Receptor Subtype System to Spatial Learning , 1999, The Journal of Neuroscience.

[29]  R. Fogari,et al.  Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring , 1999 .

[30]  Maria Larsson,et al.  Cognitive functioning in very old age , 1999 .

[31]  S. Okuyama,et al.  Role of the angiotensin II type-2 receptor in the mouse central nervous system. , 1999, Japanese journal of pharmacology.

[32]  K. Goa,et al.  Valsartan , 1997, Drugs.

[33]  R. Cabeza,et al.  Imaging Cognition: An Empirical Review of PET Studies with Normal Subjects , 1997, Journal of Cognitive Neuroscience.

[34]  B. Lernfelt,et al.  15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.

[35]  B Bornkessel,et al.  [Angiotensin II receptor antagonists]. , 1995, Medizinische Monatsschrift fur Pharmazeuten.

[36]  B. Johansson.  Pathogenesis of vascular dementia: the possible role of hypertension. , 1994, Dementia.

[37]  Ace Inhibitors: Central Actions , 1994 .

[38]  T. Groen,et al.  Impaired learning and memory in mature spontaneously hypertensive rats , 1992, Brain Research.

[39]  L. Whalley,et al.  Senile hypertension and cognitive impairment: an overview. , 1992, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[40]  T. Hedner,et al.  Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. , 1992, Blood pressure.

[41]  B. Costall,et al.  Cognitive enhancing actions of PD123177 detected in a mouse habituation paradigm. , 1990, NeuroReport.

[42]  N. Wright,et al.  Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood. , 1990, British journal of clinical pharmacology.

[43]  B. Costall,et al.  Cognitive enhancing actions of DuP 753 detected in a mouse habituation paradigm. , 1990, Neuroreport.

[44]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[45]  B. Costall,et al.  Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro , 1989, Brain Research.

[46]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[47]  J. Braszko,et al.  Psychotropic effects of angiotensin II and III in rats: Locomotor and exploratory vs cognitive behaviour , 1987, Behavioural Brain Research.

[48]  E. Kaplan,et al.  The Boston naming test , 2001 .

[49]  B Isaacs,et al.  The Set Test as an Aid to the Detection of Dementia in Old People , 1973, British Journal of Psychiatry.